Fairfield Financial Advisors, LTD Gilead Sciences, Inc. Transaction History

Fairfield Financial Advisors, LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 04, 2024	BUY	$77.31 - $88.08 $8,117 - $9,248	105 New	105 $8.55 Million
Q4 2022 Oct 07, 2024	SELL	$62.32 - $89.47 $10,282 - $14,762	-165 Reduced 44.59%	205 $17.6 Million
Q3 2022 Oct 07, 2024	BUY	$59.54 - $68.01 $22,029 - $25,163	370 New	370 $22.8 Million
Q2 2022 Oct 07, 2024	BUY	$57.72 - $65.01 $21,356 - $24,053	370 New	370 $22.9 Million
Q1 2022 Oct 07, 2024	BUY	$57.92 - $72.58 $26,064 - $32,661	450 New	450 $26.8 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Fairfield Financial Advisors, LTD, based on Form 13F filings with the SEC.

Stay updated on Fairfield Financial Advisors, LTD with notifications on news.